Status:
UNKNOWN
Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma
Lead Sponsor:
Inserm U955
Conditions:
Liver Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Our project is a large-scale characterisation of cHCC-CCA will allow us to determine which subsets harbor actionable gene alterations. We will also aim to improve diagnosis of this tumor type by the u...
Detailed Description
* Scientific background Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare liver cancer characterized by a dual hepatocytic and biliary differentiation. It is resistant to conventional an...
Eligibility Criteria
Inclusion
- histological diagnosis of combined tumor biological sample available
Exclusion
- unequivocal histological features
Key Trial Info
Start Date :
January 15 2001
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 30 2025
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06146127
Start Date
January 15 2001
End Date
January 30 2025
Last Update
November 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Julien Calderaro
Créteil, France, 94010